BOSTER[®] antibody and ELISA experts

BOSTER BIOLOGICAL TECHNOLOGY

Building C21, 3rd to 5th Floors, Optics Valley Biopharmaceutical Accelerator, East Lake High-Tech Development Zone, Wuhan.

Web: www.boster.com Phone: 027-67845390/1/2 Email: boster@boster.com

Basic Information	
Product Name	Anti-MMP8 Antibody
Gene Name	MMP8
Source	Rabbit
Clonality	Polyclonal
lsotype	lgG
Species Reactivity	human
Tested Application	WB, IHC
Contents	500 ug/ml antibody with PBS, 0.02% NaN3, 1 mg/ml BSA and 50% glycerol.
Immunogen	A synthetic peptide corresponding to a sequence at the N-terminus of human MMP8, different from the related rat and mouse sequences by three amino acids.
Concentration	500 ug/ml
Purification	Immunogen affinity purified.
Observed MW	53 kDa
Dilution Ratios	Western blot (WB):1:500-2000Immunohistochemistry (IHC):1:50-400(Boiling the paraffin sections in 10mM citrate buffer,pH6.0,or PH8.0 EDTA repair liquid for 20mins is required for the staining of formalin/paraffin sections.) Optimal working dilutions must be determined by end user.

Storage

12 months from date of receipt, -20°C as supplied.


Background Information

MMP8(Matrix metalloproteinase 8) is a member of the family of matrix metalloproteinases. It is distinct from the collagenase of skin fibroblasts and synovial cells in substrate specificity and immunologic crossreactivity. MMP8 was mapped to 11q21-q22. MMP8 is an enzyme that degrades fibrillar collagens imparting strength to the fetal membranes, is expressed by leukocytes and chorionic cytotrophoblast cells. The enzyme exhibits 58% homology to human fibroblast collagenase and has the same domain structure. It consists of a 20-residue signal peptide, and an 80-residue propeptide that is lost on autolytic activation by cleavage of an M-L bond. MMP8 was found to possess 57% identity with the deduced protein sequence for fibroblast collagenase with 72% chemical similarity. Matrix metalloproteinases(MMPs) have fundamental roles in tumor progression, but most clinical trials with MMP inhibitors have not shown improvements in individuals with cancer. MMP8 has a paradoxical protective role in cancer and provides a genetic model to evaluate the molecular basis of gender differences in cancer susceptibility.

antibody and ELISA experts BOSTER BIOLOGICAL TECHNOLOGY Building C21, 3rd to 5th Floors, Optics Valley Biopharmaceutical Accelerator, East Lake High-Tech Development Zone, Wuhan.

Web: www.boster.com Phone: 027-67845390/1/2 Email: boster@boster.com


Selected Validation Data



Western blot analysis of MMP8 using anti-MMP8 antibody (BA0572). The sample well of each lane was loaded with 30 ug of sample under reducing conditions.

Lane 1: human MCF-7 whole cell lysates.

After electrophoresis, proteins were transferred to a membrane. Then the membrane was incubated with rabbit anti-MMP8 antigen affinity purified polyclonal antibody (BA0572) at a dilution of 1:1000 and probed with a goat anti-rabbit IgG-HRP secondary antibody (Catalog # BA1054). The signal is developed using ECL Plus Western Blotting Substrate (Catalog # AR1197). A specific band was detected for MMP8 at approximately 53 kDa. The expected band size for MMP8 is at 53 kDa.



IHC analysis of MMP8 using anti-MMP8 antibody (BA0572). MMP8 was detected in a paraffin-embedded section of human breast cancer tissue. The tissue section was incubated with rabbit anti-MMP8 Antibody (BA0572) at a dilution of 1:200 and developed using HRP Conjugated Rabbit IgG Super Vision Assay Kit (Catalog # SV0002) with DAB (Catalog # AR1027) as the chromogen.